Results 31 to 40 of about 32,649 (166)
Frontiers in ImmunologyObjectiveWhile observational studies link immune cells with post-stroke functional outcome, the underlying immune mechanisms are not well understood.
Weiming Sun +16 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2017 Background Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse.
Dina Schneider +8 more
doaj +1 more source
Design of a Water-Soluble CD20 Antigen with Computational Epitope Scaffolding
Protein ScienceAbstract The poor solubility of integral membrane proteins in water frequently hinders studies with these proteins, presenting challenges for structure determination and binding screens. For instance, the transmembrane protein CD20, which is an important target for treating B-cell malignancies, is not soluble in water
Zhiyuan Yao, Brian Kuhlman
openaire +3 more sources
Análise da rejeição do transplante de aponeurose em coelhos
Einstein (São Paulo)OBJETIVO: Estudar a viabilidade de aponeurose heteróloga para fechar parede abdominal de coelhos, com ênfase no processo de rejeição. MÉTODOS: Este projeto foi aprovado pelo Comitê de Cuidados Animais da Faculdade de Ciências Médicas da Santa Casa de São
Andre Ibrahim David +7 more
doaj +1 more source
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. [PDF]
PLoS ONE, 2014 The humanized anti-CD22 antibody, epratuzumab, has demonstrated therapeutic activity in clinical trials of lymphoma, leukemia and autoimmune diseases, treating currently over 1500 cases of non-Hodgkin lymphoma, acute lymphoblastic leukemias, Waldenström ...
Edmund A Rossi +2 more
doaj +1 more source
Frontiers in ImmunologyCD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting ...
Yuejiao Huang +7 more
doaj +1 more source
Immunotherapy for B-cell lymphoma: current status and prospective advances
Frontiers in Immunology, 2012 Therapy for non-Hodgkin's lymphoma has progressed significantly over the last decades. However, the majority of patients remain incurable, and novel therapies are needed.
Nurit eHollander
doaj +1 more source
Selection of an Anti-CD20, Single-Chain Antibody by Phage ELISA on Fixed Cells
BioTechniques, 1999 Cloning the correct genes that code for antibody-variable domains from hybridomas is often complicated by the presence of several immunoglobulin transcripts, some of them arising from a myeloma cell line.
Stefanie Schmidt +3 more
doaj +1 more source
B-cell depletion therapy for multiple sclerosis
Immunological Medicine, 2021 Since the initial observation of increased immunoglobulin concentrations in the cerebrospinal fluid of multiple sclerosis (MS) patients in the 1940s, B cells have been considered to participate in the pathology of MS through the production of ...
Yusei Miyazaki, Masaaki Niino
doaj +1 more source
FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20 [PDF]
Cytometry, 1998 Most antibody panels proposed for flow cytometric immunophenotyping of non-Hodgkin's lymphomas and chronic lymphoid leukemias include anti-CD20 and FMC7 antibodies. As in our experience, reactivity of B-cells with these antibodies seemed to be correlated, we evaluated whether the simultaneous use of anti-CD20 and FMC7 antibodies is justified.
W, Hübl, J, Iturraspe, R C, Braylan
openaire +2 more sources